Hikma Pharmaceuticals resumes the launch of its generic version of GSK’s Advair Diskus

Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC (LON:HIK), the multinational pharmaceutical company, has announced that it has resumed the launch of its generic version of GlaxoSmithKline’s Advair Diskus®1 in the US following US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application in January 2021. The amendment reflected enhanced packaging controls to meet new industry standards adopted since the initial submission of its ANDA. 

Hikma will immediately resume launch activities of its generic product for Advair Diskus® (Fluticasone Propionate and Salmeterol Inhalation Powder, USP), 100mcg/50mcg and 250mcg/50mcg doses in the US.

Siggi Olafsson, Chief Executive Officer of Hikma Pharmaceutical, said: “We appreciate the FDA’s timely review and approval of our amendment and are now immediately resuming the launch of our high quality, substitutable generic version of Advair Diskus®. We are very pleased to improve availability of this critical medicine for patients and healthcare providers in the US.”

1 Advair® and Advair Diskus® are registered trademarks of GSK group of companies.

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on whatsapp
WhatsApp